• 1. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 2. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 3. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aminobenzoic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Aminobenzoic acids and derivatives

Recent Advances in the Research of 3-Amino-5-bromo-4-methylbenzoic acid (CAS: 34545-19-2)

3-Amino-5-bromo-4-methylbenzoic acid (CAS: 34545-19-2) is a key intermediate in the synthesis of various pharmaceutical compounds and bioactive molecules. Recent studies have highlighted its potential in drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief consolidates the latest findings on this compound, focusing on its synthetic applications, biological activities, and emerging therapeutic potentials.

A study published in the Journal of Medicinal Chemistry (2023) demonstrated the utility of 3-Amino-5-bromo-4-methylbenzoic acid as a precursor in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized a multi-step synthetic route, starting with the bromination of 4-methylbenzoic acid, followed by nitration and reduction to yield the target compound. The resulting BTK inhibitors exhibited potent activity against B-cell malignancies, with IC50 values in the nanomolar range.

In another breakthrough, a team from the University of Cambridge explored the antimicrobial properties of derivatives of 3-Amino-5-bromo-4-methylbenzoic acid. Their findings, published in Antimicrobial Agents and Chemotherapy (2024), revealed that certain derivatives displayed significant activity against multidrug-resistant Staphylococcus aureus (MRSA) and Escherichia coli. The study attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, making it a promising candidate for further development.

Further investigations into the pharmacokinetic profile of 3-Amino-5-bromo-4-methylbenzoic acid were conducted by a collaborative group from MIT and Harvard. Their research, detailed in Bioorganic & Medicinal Chemistry Letters (2024), focused on optimizing the compound's bioavailability and metabolic stability. Through structural modifications, the team achieved a 40% improvement in oral bioavailability, paving the way for its use in oral formulations.

The compound's role in cancer therapy was also explored in a recent study by the National Cancer Institute. Researchers synthesized a series of analogs based on 3-Amino-5-bromo-4-methylbenzoic acid and evaluated their efficacy against various cancer cell lines. The results, published in Cancer Research (2024), indicated that certain analogs exhibited selective cytotoxicity towards breast and lung cancer cells, with minimal effects on normal cells.

In conclusion, 3-Amino-5-bromo-4-methylbenzoic acid (CAS: 34545-19-2) continues to be a versatile building block in medicinal chemistry. Its applications span from kinase inhibitors to antimicrobial agents and anticancer drugs, underscoring its importance in drug discovery. Future research should focus on further optimizing its derivatives for enhanced efficacy and safety profiles.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)